GR1803

GR1803 is an investigational agent whose form is not stated in the registry developed by Genrix (Shanghai) Biopharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07452198 (A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma), in multiple myeloma. The largest, NCT07452198, plans to enrol 358 participants with primary completion expected 2029-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.